198 related articles for article (PubMed ID: 9014009)
1. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
Kageyama S; Katsumoto T; Taniguchi K; Ismail SI; Shimmen T; Sasao F; Gao M; Owatari S; Wakamiya N; Tsuchie H; Ueda S; Shiraki K; Kurimura T
Acta Virol; 1996 Sep; 40(4):195-200. PubMed ID: 9014009
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
Tewari D; Notkins AL; Zhou P
J Gene Med; 2003 Mar; 5(3):182-9. PubMed ID: 12666184
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
4. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
6. [Anti-HIV-1 p17 antibody as anti-HIV agent].
Tsuchie H; Tochikura A; Kageyama S; Kurimura T
Nihon Rinsho; 1993 Sep; 51 Suppl():213-8. PubMed ID: 8271386
[No Abstract] [Full Text] [Related]
7. A prospective study on correlation between the decrease in anti-P17 antibody level and progression to AIDS in asymptomatic carriers of HIV.
Choudhury AM; Yamada O; Wakamiya N; Kurimura T
Microbiol Immunol; 1992; 36(8):833-40. PubMed ID: 1474934
[TBL] [Abstract][Full Text] [Related]
8. cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication.
Tewari D; Goldstein SL; Notkins AL; Zhou P
J Immunol; 1998 Sep; 161(5):2642-7. PubMed ID: 9725267
[TBL] [Abstract][Full Text] [Related]
9. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
10. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
11. Three antigenic regions in p17 of human immunodeficiency virus type 1 (HIV-1) revealed by mouse monoclonal antibodies and human antibodies in HIV-1 carrier sera.
Liu X; Ota A; Watanabe M; Ueda S; Saitoh A; Shinagawa H; Nakata A; Kurimura T; Wang X; Zhao Y
Microbiol Immunol; 1995; 39(10):775-85. PubMed ID: 8577268
[TBL] [Abstract][Full Text] [Related]
12. Random expression of human immunodeficiency virus-1 (HIV-1) p17 (epitopes) on the surface of the HIV-1-infected cell.
Ota A; Liu X; Fujio H; Sakato N; Ueda S
Hybridoma; 1998 Feb; 17(1):73-5. PubMed ID: 9523241
[TBL] [Abstract][Full Text] [Related]
13. Fine specificity of IgG subclass response to group antigens in HIV-1-infected patients.
Broliden PA; Morfeldt-Månsson L; Rosen J; Jondal M; Wahren B
Clin Exp Immunol; 1989 May; 76(2):216-21. PubMed ID: 2503275
[TBL] [Abstract][Full Text] [Related]
14. Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.
Shang F; Huang H; Revesz K; Chen HC; Herz R; Pinter A
J Virol; 1991 Sep; 65(9):4798-804. PubMed ID: 1714518
[TBL] [Abstract][Full Text] [Related]
15. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
16. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells.
Ota A; Bautista AN; Yadav ML; Ueda S
Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
18. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
de Goede AL; Boers PH; Dekker LJ; Osterhaus AD; Gruters RA; Rimmelzwaan GF
Vaccine; 2009 Sep; 27(42):5735-9. PubMed ID: 19647812
[TBL] [Abstract][Full Text] [Related]
19. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases.
Davis D; Donners H; Willems B; Vermoesen T; Heyndrickx L; Colebunders R; van der Groen G
J Med Virol; 2003 Nov; 71(3):332-42. PubMed ID: 12966537
[TBL] [Abstract][Full Text] [Related]
20. HIV p17 reverses the anti-inflammatory activity of IL-4 on IL-15 stimulated monocytes and modulates their ability to secrete MIP-1 alpha.
De Francesco MA; Poiesi C; Ricotta D; Manca N
Virus Res; 2006 Jun; 118(1-2):170-7. PubMed ID: 16427155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
